Pharmaphorum interviewed VivoSense Chief Product Officer and co-founder Dudley Tabakin and new board members from Xontogeny and Debiopharm to discuss how VivoSense’s recent $25M Series A Financing round will help scale up VivoSense® software and accelerate the use of wearable sensors data in clinical trials.
Debiopharm Innovation Fund is an evergreen fund investing in digital health companies transforming patient journeys and pharmaceutical R&D. Xontogeny is a life sciences accelerator that collaborates with entrepreneurs, scientific founders and first-time CEOs to drive the successful development of their technologies to enable new treatment options for patients with serious diseases.
 |
|
 |
“We were really searching for the right investment in this emerging digital space. We’ve always been intrigued by wearables but haven’t seen a lot that has measured up until we met VivoSense. We think wearables that use these types of technologies will have an edge and be differentiated from those that use existing platforms in future clinical trials.” ~ Chris Garabedian, Founder, Xontogony |
 |
|
Read the full article on the Pharmaphorum website: Digital Investment Promises To Accelerate The Use Of Wearable Sensor Data In Clinical Trials.
You can also watch the following on-demand webinar to hear Dudley speak about 3 critical steps to ensure meaningful data.
